The Interplay between Alpha-Synuclein Clearance and Spreading

被引:84
|
作者
da Fonseca, Tomas Lopes [1 ,2 ]
Villar-Pique, Anna [1 ]
Outeiro, Tiago Fleming [1 ,2 ,3 ]
机构
[1] Univ Med Ctr Gottingen, Dept Neurodegenerat & Restorat Res, Ctr Nanoscale Microscopy & Mol Physiol Brain, D-37073 Gottingen, Germany
[2] Univ Lisbon, Inst Fisiol, Fac Med, P-1649028 Lisbon, Portugal
[3] Univ Nova Lisboa, CEDOC, Fac Ciencias Med, P-1150 Lisbon, Portugal
来源
BIOMOLECULES | 2015年 / 5卷 / 02期
关键词
D O I
10.3390/biom5020435
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinson's Disease (PD) is a complex neurodegenerative disorder classically characterized by movement impairment. Pathologically, the most striking features of PD are the loss of dopaminergic neurons and the presence of intraneuronal protein inclusions primarily composed of alpha-synuclein (alpha-syn) that are known as Lewy bodies and Lewy neurites in surviving neurons. Though the mechanisms underlying the progression of PD pathology are unclear, accumulating evidence suggests a prion-like spreading of alpha-syn pathology. The intracellular homeostasis of alpha-syn requires the proper degradation of the protein by three mechanisms: chaperone-mediated autophagy, macroautophagy and ubiquitin-proteasome. Impairment of these pathways might drive the system towards an alternative clearance mechanism that could involve its release from the cell. This increased release to the extracellular space could be the basis for alpha-syn propagation to different brain areas and, ultimately, for the spreading of pathology and disease progression. Here, we review the interplay between alpha-syn degradation pathways and its intercellular spreading. The understanding of this interplay is indispensable for obtaining a better knowledge of the molecular basis of PD and, consequently, for the design of novel avenues for therapeutic intervention.
引用
收藏
页码:435 / 471
页数:37
相关论文
共 50 条
  • [41] Alpha-Synuclein Animal Models
    Aebischer, P.
    MOVEMENT DISORDERS, 2010, 25 : S606 - S606
  • [42] Alpha-Synuclein Therapeutic Opportunities
    Trojanowski, J.
    MOVEMENT DISORDERS, 2010, 25 : S606 - S606
  • [43] Intercellular transmission of alpha-synuclein
    Wu, Shenjie
    Schekman, Randy W.
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2024, 17
  • [44] Gastrointestinal Immunity and Alpha-Synuclein
    Barbut, Denise
    Stolzenberg, Ethan
    Zasloff, Michael
    JOURNAL OF PARKINSONS DISEASE, 2019, 9 : S313 - S322
  • [45] Alpha-Synuclein Is a Cellular Ferrireductase
    Davies, Paul
    Moualla, Dima
    Brown, David R.
    PLOS ONE, 2011, 6 (01):
  • [46] alpha-synuclein in Lewy bodies
    Spillantini, MG
    Schmidt, ML
    Lee, VMY
    Trojanowski, JQ
    Jakes, R
    Goedert, M
    NATURE, 1997, 388 (6645) : 839 - 840
  • [47] Alpha-Synuclein Biology and Biochemistry
    Lee, V.
    MOVEMENT DISORDERS, 2010, 25 : S606 - S606
  • [48] Alpha-synuclein and neurodegenerative diseases
    Goedert, M
    NATURE REVIEWS NEUROSCIENCE, 2001, 2 (07) : 492 - 501
  • [49] Alpha-Synuclein: a new evidence?
    Meissner, W.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 891 - 891
  • [50] Salivary alpha-synuclein in aging
    Vivacqua, G.
    Fabbrini, A.
    Suppa, A.
    Mancinelli, R.
    Fabbrini, G.
    Colosimo, C.
    Berardelli, A.
    MOVEMENT DISORDERS, 2017, 32